Various approaches targeting PSMA have been developed since 1987 when PSMA was discovered as an antigen specifically recognized by the 7E11-C5 monoclonal antibody (7E11-mAb) raised against LNCaP (a PSMA-positive prostate adenocarcinoma-derived cell line) lysates (17). This evidence concerns the gene FOLH1 and prostate adenocarcinoma.